RBC Capital maintains IDEAYA Biosciences at Outperform, lowers price target to $45 from $48

What happened

RBC Capital kept its Outperform rating on IDEAYA Biosciences but cut its price target to $45 from $48, a 6.2% decrease. The new target implies 43.6% upside from the November 3 closing price of $31.33.

Confirmed

Global impact / market context

The lower target signals that RBC sees less potential share-price appreciation than before, while retaining its positive rating. For investors, analyst targets can shape expectations and positioning, but they are opinions rather than company results or guaranteed future prices.

Analyst inference

Recent analyst targets listed in the article range from $48 to $63 across five notes from the past 30 days, placing RBC’s new $45 target below that range. The article does not explain the reason for RBC’s change or describe a company event.

Confirmed

What to watch

1. Check for a later RBC rating or target update; another change could alter the analyst’s stated view of IDEAYA’s potential share-price performance. Analyst inference
2. Watch for company disclosures that explain business performance or plans, since those facts could provide context for analysts’ future estimates and ratings. Analyst inference
3. Compare subsequent analyst targets with the reported $45 RBC target and the listed $48-to-$63 range to see whether views converge or diverge. Analyst inference

Evidence

• Original source link unavailable